Suvretta Capital Management, L Acquires 10,215 Shares of Benitec Biopharma (NASDAQ:BNTC) Stock

Benitec Biopharma Limited (NASDAQ:BNTC) Director Suvretta Capital Management, L acquired 10,215 shares of the firm’s stock in a transaction on Thursday, December 18th. The stock was bought at an average price of $11.24 per share, with a total value of $114,816.60. Following the completion of the acquisition, the director directly owned 9,546,875 shares in the company, valued at approximately $107,306,875. This represents a 0.11% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Suvretta Capital Management, L also recently made the following trade(s):

• On Monday, December 22nd, Suvretta Capital Management, L bought 19,542 shares of Benitec Biopharma stock. The shares were bought at an average cost of $12.08 per share, for a total transaction of $236,067.36.
• On Friday, December 19th, Suvretta Capital Management, L purchased 16,384 shares of Benitec Biopharma stock. The shares were bought at an average price of $11.48 per share, for a total transaction of $188,088.32.
• On Friday, November 7th, Suvretta Capital Management, L acquired 1,481,481 shares of Benitec Biopharma stock. The stock was bought at an average price of $13.50 per share, with a total value of $19,999,993.50.

Benitec Biopharma Trading Up 7.4%

Shares of BNTC stock traded up $0.85 during midday trading on Monday, reaching $12.35. 143,304 shares of the stock were exchanged, compared to its average volume of 237,340. Benitec Biopharma Limited has a 1 year low of $9.70 and a 1 year high of $17.15. The company’s 50 day moving average is $13.81 and its two-hundred day moving average is $13.46. The firm has a market cap of $418.17 million, a PE ratio of -10.21 and a beta of 0.20.

Benitec Biopharma (NASDAQ:BNTC) last released its earnings results on Friday, November 14th. The biotechnology company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.13. As a group, equities analysts expect that Benitec Biopharma Limited will post -1.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on BNTC shares. JMP Securities set a $22.00 target price on shares of Benitec Biopharma in a research note on Tuesday, November 4th. Citigroup reiterated an “outperform” rating on shares of Benitec Biopharma in a research note on Tuesday, November 4th. Citizens Jmp increased their target price on Benitec Biopharma from $20.00 to $22.00 and gave the stock a “market outperform” rating in a research note on Tuesday, November 4th. Oppenheimer restated an “outperform” rating and set a $29.00 price target (down from $35.00) on shares of Benitec Biopharma in a report on Tuesday, September 16th. Finally, Zacks Research upgraded shares of Benitec Biopharma from a “strong sell” rating to a “hold” rating in a research note on Friday, November 14th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $26.25.

Institutional Investors Weigh In On Benitec Biopharma

Institutional investors have recently modified their holdings of the business. Goldman Sachs Group Inc. purchased a new position in Benitec Biopharma in the 1st quarter worth about $597,000. Infinitum Asset Management LLC lifted its position in Benitec Biopharma by 435.7% during the first quarter. Infinitum Asset Management LLC now owns 1,125,000 shares of the biotechnology company’s stock valued at $14,636,000 after purchasing an additional 915,000 shares during the period. MYDA Advisors LLC boosted its holdings in Benitec Biopharma by 4.0% in the first quarter. MYDA Advisors LLC now owns 52,000 shares of the biotechnology company’s stock worth $677,000 after purchasing an additional 2,000 shares during the last quarter. AWM Investment Company Inc. grew its position in Benitec Biopharma by 35.2% in the 1st quarter. AWM Investment Company Inc. now owns 137,977 shares of the biotechnology company’s stock worth $1,795,000 after purchasing an additional 35,950 shares during the period. Finally, XTX Topco Ltd purchased a new stake in Benitec Biopharma during the 2nd quarter valued at $127,000. 52.19% of the stock is owned by hedge funds and other institutional investors.

Benitec Biopharma Company Profile

Benitec Biopharma Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.

Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.